Company intelligence / Profile preview

Neumann Advisors

Central, Hong Kong

Ownership: Private
Development stage: Other

Overview

Neumann Advisors is an asset management and investment firm founded in 2016 by experienced technology investors. The firm focuses on building a world-class investment platform and has participated as an investor in biotechnology companies such as Helixon US Inc., which specializes in antibody design. There is no evidence that Neumann Advisors develops its own therapeutic products or platforms.

Industry: Investors

Partnerships

Gaorong CapitalXiang He CapitalHillhouse InvestmentWuyuan CapitalQingzhi Capital for Helixon US Inc.

Beyond the preview

Go deeper on Neumann Advisors.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neumann Advisors.

Explore the full profile